Compare Fiverr International Ltd (FVRR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs GSK plc — how do they compare? Fiverr International Ltd trades at $8.72 (market cap $310.61M), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 295.8× Fiverr International Ltd's market cap, and GSK plc pays a 3.9% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and GSK plc for 93 Days on average.
| FVRR | GSK | |
|---|---|---|
Market Cap | $310.61M | $91.88B |
Volume | 381,459 | 7,730,529 |
Sector | Media | Health |
52-Week High | $23.60 | $61.18 |
52-Week Low | $8.47 | $43.24 |
Typical Hold Time | 62 Days | 93 Days |
Enterprise Value | $63.00M | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.64, up 1.65% on the day, but remains in a bearish technical trend with recent earnings misses. The company reported Q2 2026 revenue of $97.8 million, down 10% year-over-year, as AI disruption pressures demand for lower-value freelance work. Valuation ratios appear attractive with a P/E of 10.67 and P/S of 0.76, yet growth concerns persist. Analyst sentiment is cautious with a consensus price target of $10.50 and 76% hold ratings.
The outlook is mixed: low valuations and a high gross margin of 82% offer value, but AI-driven revenue compression and consecutive earnings misses pose significant risks. Upside depends on stabilizing freelance demand and successful adaptation to AI trends, while downside risks include prolonged competitive pressure and execution challenges in a shifting gig economy.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
